Finally, CD44 signaling has also been reported to increase resistance to chemotherapy in HNSCC 23, which together with previously published data and our study all imply CD44 as a negative prognostic factor 8–19. The gene discussed is CD44; the disease is head and neck squamous cell carcinoma.